TGA / PMDA / NMPA · Asia-Pacific
management — TGA / PMDA / NMPA regulatory status
management regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 43 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 20210184 | Phase 3 | Amgen | 2024-515523-11-00 |
| AMG 133, Placebo for Maridebart Cafraglutide | Phase 3 | Amgen | 2024-515524-36-00 |
| APHP210090 | Phase 3 | PARItec | 2024-516058-23-00 |
| DEXMEDETOMIDINE , 18F-DPA-714 | Phase 3 | PARItec | 2024-511898-30-00 |
| Enhanced standard management | Phase 3 | United Therapeutics Europe | NCT01819662 |
| Exparel | Phase 3 | Pacira Ireland | NCT03428984, NCT03485014 |
| Recovery Management Checkups (RMC) | Phase 3 | BRIGHT MINDS BIOSCIENCES | NCT01153594 |
| Tramadol | Phase 3 | AVENUE THERAPEUTICS | NCT03290378, NCT03395808 |
| Transitional Case Management Study | Phase 3 | BRIGHT MINDS BIOSCIENCES | NCT00264329 |
| patients were assigned to receive TNT or iTNT management | Phase 3 | Chinese Academy of | NCT07070622 |
| strengths-based case management | Phase 3 | BRIGHT MINDS BIOSCIENCES | NCT00780260 |
| Aleniglipron or Placebo | Phase 2 | Structure Therapeutics | NCT06693843, NCT07169942 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 12329909 | Airway management systems for pulmonary disorder treatment | US |
| 11890415 | Airway management systems for pulmonary disorder treatment | US |
| 11666634 | Methods and compositions for management of gastrointestinal disorders | US |
| 11450420 | Secure smart dosing system with automated delivery, measurement, and management for pills | US |
| 11083850 | Secure smart dosing system with automated delivery, measurement, and management | US |
| 10736880 | Therapeutics for preterm labor management | US |
| 8715751 | Artemisinins in the clinical and veterinary management of kinetoplastid infections | US |
| 2012249536 | Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases | AU |
| 8546348 | Upregulation of opioid receptors for management | US |
| 8469899 | Management of gastro-intestinal disorders | US |
| 8435960 | Devices for improved wound management | US |
| 8153690 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of management?
management currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get management regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to management?
This spoke lists 43 published programs associated with management in our pipeline index.